EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis

Dong Cai iD, Guo-Chao Zhong iD, Xin Dai, Zhibo Zhao, Menglin Chen, Jiejun Hu, Zhenru Wu, Lve Cheng, Shengwei Li, Jianping Gong iD

Advanced Science · 2025

DOI: 10.1002/advs.202411719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Dong Cai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Proto-Oncogene Proteins c-akt, Hepatocyte Nuclear Factor 4. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chongqing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting cholesterol metabolism is a novel direction for tumor therapy. Unfortunately, the current use of statins for hepatocellular carcinoma (HCC) is controversial. Herein, farnesyl‐diphosphate farnesyltransferase 1 (FDFT1) is identified as a novel target for treating HCC and a potential alternative to statins. Twenty‐three key genes in cholesterol biosynthesis are screened, and FDFT1 is identified via public databases (The Cancer Genome Atlas, International Cancer Genome Consortium and Gene Expression Omnibus). Clinical samples reveal that FDFT1 is highly expressed in HCC tissues, and this phenotype is strongly associated with a poor prognosis. Functionally, FDFT1 knockdown inhibits the proliferation and metastasis of HCC cells and suppresses hepatocarcinogenesis in vitro and in vivo, whereas FDFT1 overexpression promotes HCC cell proliferation and metastasis. Mechanistically, FDFT1 downregulation decreases cholesterol and bile acid levels and then increases hepatocyte nuclear factor 4 alpha (HNF4A) transcriptional activity. Experiments indicate that HNF4A combines with the promoter of aldolase B ( ALDOB) and promotes the ALDOB transcription and that ALDOB combines with AKT serine/threonine kinase 1 (AKT1) and inhibits AKT1 phosphorylation. Moreover, FDFT1 knockdown combined with AKT inhibitor (AZD5363) treatment shows remarkable therapeutic potential. FDFT1 inhibition reduces cholesterol and bile acid levels to delay HCC progression through the HNF4A/ALDOB/AKT1 axis. Thus, targeting FDFT1 may be a novel potential strategy for treating HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsProto-Oncogene Proteins c-aktHepatocyte Nuclear Factor 4CholesterolBile Acids and SaltsFarnesyl-Diphosphate FarnesyltransferaseHumansMiceAnimalsDisease ProgressionCell Line, TumorCell Proliferation

Stichwörter der Autor:innen

FDFT1bile acidcholesterolhepatocellular carcinomaproliferation

Substanzen

Proto-Oncogene Proteins c-aktHepatocyte Nuclear Factor 4CholesterolBile Acids and SaltsFarnesyl-Diphosphate FarnesyltransferaseHNF4A protein, humanAKT1 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
  • Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.

ORCID-Profile: Dong Cai, Guo-Chao Zhong, Jianping Gong

Förderung

  • National Natural Science Foundation of China
  • Chongqing Natural Science Foundation

Zitieren

APA

Cai, D., Zhong, G. C., Dai, X., Zhao, Z., Chen, M., Hu, J., Wu, Z., Cheng, L., Li, S., & Gong, J. (2025). Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. Advanced Science. https://doi.org/10.1002/advs.202411719

Vancouver

Cai D, Zhong GC, Dai X, Zhao Z, Chen M, Hu J, et al. Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. Advanced Science. 2025. doi:10.1002/advs.202411719

BibTeX
@article{Cai2025,
  author = {Cai, Dong and Zhong, Guo-Chao and Dai, Xin and Zhao, Zhibo and Chen, Menglin and Hu, Jiejun and Wu, Zhenru and Cheng, Lve and Li, Shengwei and Gong, Jianping},
  title = {Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202411719}
}
Kostenlos starten →